After Yusimry’s discount, future prices for Adalimumab are unclear
Adalimumab, sold under the brand name Humira, has long been one of the best-selling drugs in the world. But its 20-year period without competition has ended, and despite its best efforts to delay its arrival, drugmaker AbbVie now faces increasing competition from biosimilars entering the market. But a biosimilar about to be launched could be … Read more